Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by GrahamBon Nov 01, 2023 12:16pm
116 Views
Post# 35711459

Sales Update

Sales UpdateJust checking in to see if there is any evidence of actual sales.

Anxious waiting again for conference calls, but were any sales actually announced?

Looking back at the recent press releases-it seems we are stuck in a waiting period, where no sales happen. 
So odd, when the posters talk about how much cardiologists want the product....

Oh well keep waiting I guess.

 
 
 “The Company has aggressively marketed its VMS+ products at 12 medical conferences this year and engaged hundreds of clinicians.  The Company had set a target of 40-45 systems committed to customers by year end.  The company has received 6 purchase orders year to date, including orders from Europe, UK, and United States, has 3 installations being arranged and 5 more purchase orders are expected by end of January. 
 
 
 The Company has completed arrangements with 9 regional distributors in the USA, which taken together cover the entire country (see listing on the company’s website). These US-based distributors plus our UK (CardioLogic) and European distributor (AngioPro) and internal staff forms a team of 33 representatives calling on cardiologists. All these representatives are now fully trained and actively following up with their existing customers, as well as the regional leads which were acquired from medical conferences.  
 
 
 With the assistance of our distributors and our internal sales force, the Company now has a list of over 4,000 cardiologists who have a practice where the VMS+ would improve their ability to assess and monitor their patients In addition, our sales team (direct and distributor) already have a relationship with all these potential customers in US, UK and Europe.  Hence, the Company now has a full funnel of leads. Our sales team has been actively scheduling appointments to make them aware of the clinical benefits of the VMS+. 
 
 
 The Company continues to be actively working with General Electric HealthCare Corporation (GEHC) through their Edison Development Program1 to bring our cardiac analysis tools to their existing customer base.  GEHC is currently being spun out to become a stand-alone company to allow tailored decisions in line with distinct strategies and industry-specific dynamics to accelerate growth across the continuum of care with focused organic investment and strategic M&A.2 “
 
https://newsdirect.com/news/ventripoint-diagnostics-provides-a-corporate-update-and-announces-new-investor-relations-initiative-788600247
 
What really happened? 
The story of 2s
 
EDISON is still waiting -2+ years
Sales are still waiting
Looks like the trading is very thin and likely just amongst longs going back-and-forth between themselves while they tell stories about what will be
<< Previous
Bullboard Posts
Next >>